EBS: Streamlined, debt-reduced, and innovation-focused, the firm leads in global biodefense and public health
A leading provider of medical countermeasures, the firm has streamlined operations, reduced debt, and expanded its global footprint. Key products like NARCAN and new pipeline innovations drive growth, while R&D targets emerging threats such as AI-generated pathogens.Based on Emergent BioSolutions I…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.